文献速递神经免疫

Ponesimod与特立氟胺治疗复发型多发性硬化的3期OPTIMUM研究

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2021-01-01

OPTIMUM是首个比较两种口服疾病修饰疗法治疗复发型多发性硬化的3期随机双盲试验,纳入1133例患者。Ponesimod在年化复发率、疲劳、MRI活动、脑体积丢失和无疾病活动状态方面优于特立氟胺,但确认的残疾累积无显著差异,安全性特征与既往S1P受体调节剂一致。

要点

  • Ponesimod组MRI年化联合唯一活动病灶相对风险降低56%,脑体积丢失减少0.34%。

核心结论

  • Ponesimod在降低年化复发率、改善疲劳、减少MRI活动、减缓脑体积丢失和达到无疾病活动状态方面优于特立氟胺,但未显著降低确认的残疾累积。

研究设计与样本

  • 多中心、双盲、活性对照、优效性随机临床试验,2015年4月27日至2019年5月16日入组1133例18至55岁复发型多发性硬化患者,按1:1随机接受每日一次20 mg ponesimod或14 mg特立氟胺治疗108周。

主要发现

  • 治疗中出现的不良事件发生率相似(88.8% vs 88.2%),严重不良事件相似(8.7% vs 8.1%),因不良事件停药在ponesimod组更常见(8.7% vs 6.0%)。

临床怎么用

  • 对于复发型多发性硬化患者,ponesimod可作为优于特立氟胺的口服治疗选择,尤其关注降低复发和MRI活动。
  • 使用ponesimod需注意因不良事件停药率略高,并遵循14天起始剂量递增以减轻首剂心脏效应。
  • 残疾累积的获益未显著优于特立氟胺,临床决策需结合患者个体情况。

局限性

  • 未报告安慰剂对照,仅与特立氟胺活性对照。
  • 随访期108周,长期残疾进展数据有限。
  • 未报告亚组分析或盲法评估细节,原文摘要未提供。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: To our knowledge, the Oral Ponesimod Versus Teriflunomide In Relapsing Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease-modifying therapies for relapsing multiple sclerosis (RMS). OBJECTIVE: To compare the efficacy of ponesimod, a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator with teriflunomide, a pyrimidine synthesis inhibitor, approved for the treatment of patients with RMS. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, double-blind, active-comparator, superiority randomized clinical trial enrolled patients from April 27, 2015, to May 16, 2019, who were aged 18 to 55 years and had been diagnosed with multiple sclerosis per 2010 McDonald criteria, with a relapsing course from the onset, Expanded Disability Status Scale (EDSS) scores of 0 to 5.5, and recent clinical or magnetic resonance imaging disease activity. INTERVENTIONS: Patients were randomized (1:1) to 20 mg of ponesimod or 14 mg of teriflunomide once daily and the placebo for 108 weeks, with a 14-day gradual up-titration of ponesimod starting at 2 mg to mitigate first-dose cardiac effects of S1P1 modulators and a follow-up period of 30 days. MAIN OUTCOMES AND MEASURES: The primary end point was the annualized relapse rate. The secondary end points were the changes in symptom domain of Fatigue Symptom and Impact Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) at week 108, the number of combined unique active lesions per year on magnetic resonance imaging, and time to 12-week and 24-week confirmed disability accumulation. Safety and tolerability were assessed. Exploratory end points included the percentage change in brain volume and no evidence of disease activity (NEDA-3 and NEDA-4) status. RESULTS: For 1133 patients (567 receiving ponesimod and 566 receiving teriflunomide; median [range], 37.0 [18-55] years; 735 women [64.9%]), the relative rate reduction for ponesimod vs teriflunomide in the annualized relapse rate was 30.5% (0.202 vs 0.290; P < .001); the mean difference in FSIQ-RMS, -3.57 (-0.01 vs 3.56; P < .001); the relative risk reduction in combined unique active lesions per year, 56% (1.405 vs 3.164; P < .001); and the reduction in time to 12-week and 24-week confirmed disability accumulation risk estimates, 17% (10.1% vs 12.4%; P = .29) and 16% (8.1% vs 9.9; P = .37), respectively. Brain volume loss at week 108 was lower by 0.34% (-0.91% vs -1.25%; P < .001); the odds ratio for NEDA-3 achievement was 1.70 (25.0% vs 16.4%; P < .001). Incidence of treatment-emergent adverse events (502 of 565 [88.8%] vs 499 of 566 [88.2%]) and serious treatment-emergent adverse events (49 [8.7%] vs 46 [8.1%]) was similar for both groups. Treatment discontinuations because of adverse events was more common in the ponesimod group (49 of 565 [8.7%] vs 34 of 566 [6.0%]). CONCLUSIONS AND RELEVANCE: In this study, ponesimod was superior to teriflunomide on annualized relapse rate reduction, fatigue, magnetic resonance imaging activity, brain volume loss, and no evidence of disease activity status, but not confirmed disability accumulation. The safety profile was in line with the previous safety observations with ponesimod and the known profile of other S1P receptor modulators. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02425644.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Kappos L, Fox RJ, Burcklen M, et al. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol. 2021. PMID: 33779698. doi:10.1001/jamaneurol.2021.0405

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。